The Pathophysiology of Repurposed Antiviral Drugs for treatment of COVID-19 Infection

Adnan Haider; Muhammad Faheem; Sayed Babar Jamal; Muhammad Naeem; Atif Ali Khan Khalil; Raees Khan; Fazli subhan

doi:10.37185/LnS.1.1.155

Adnan Haider National University of Medical Sciences, Rawalpindi
Muhammad Faheem National University of Medical Sciences, Rawalpindi
Sayed Babar Jamal National University of Medical Sciences, Rawalpindi
Muhammad Naeem National University of Medical Sciences, Rawalpindi
Atif Ali Khan Khalil National University of Medical Sciences, Rawalpindi
Raees Khan Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan,
Fazli subhan National University of Medical Sciences, Rawalpindi

DOI: https://doi.org/10.37185/LnS.1.1.155

Keywords: Covid-19, Cytokin Storm, Therapeutic Drugs, Virus

Abstract

Our planet earth has seen many viral pandemics The most recent pandemic was Severe Acute Respiratory Syndrome (SARS-CoV-2) commonly called Corona Virus disease (COVID-19). It was first reported inWuhan Peoples Republic of China, in December 2019. COVID-19 is a positive-sense single-strand enveloped RNA virus mainly found in mammals. To date, a total of six species of coronavirus have been reported that affected humans. These mainly cause respiratory, hepatic, enteric, and neurological complications. Since it is a novel virus, different therapies were used for the treatment These measures comprised of mostly repurposing of already available drugs, more specifically antiviral drugs. In this review article, we have summarized the virus- host relation and chemical structure and also discussed in detail the proposed mechanism of these repurposed antivirals drugs.

References

Krupovic M, Dolja VV, Koonin EV. Origin of viruses: primordial replicators recruiting capsids from hosts. Nature Reviews Microbiology. 2019; 17: 449-58.

Danovaro R, Dell'Anno A, Corinaldesi C, Rastelli E, Cavicchioli R, Krupovic M, et al. Virus-mediated archaeal hecatomb in the deep seafloor. Science Advances. 2016; 2: e1600492.

Chow CE, Suttle CA. Biogeography of viruses in the sea. 2015.

Raoult D, Forterre P. Redefining viruses: lessons from Mimivirus. Nature Reviews Microbiology. 2008; 6: 315-9.

Koonin EV, Wolf YI, Katsnelson MI. Inevitability of the emergence and persistence of genetic parasites caused by evolutionary instability of parasite-free states. Biology direct. 2017; 12: 1-12.

Iranzo J, Puigbò P, Lobkovsky AE, Wolf YI, Koonin EV. Inevitability of genetic parasites. Genome biology and evolution. 2016; 8: 2856-69.

Koonin EV, Dolja VV. A virocentric perspective on the evolution of life. Current opinion in virology. 2013; 3: 546- 57.

Koonin EV. Viruses and mobile elements as drivers of evolutionary transitions. Philosophical Transactions of the Royal Society B: Biological Sciences. 2016; 371: 20150442.

Frank JA, Feschotte C. Co-option of endogenous viral sequences for host cell function. Current opinion in virology. 2017; 25: 81-9.

Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. New England journal of medicine. 2003; 348: 1953-66.

Peiris J, Lai S, Poon L, Guan Y, Yam L, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. The Lancet. 2003; 361: 1319-25.

Li F. Structure, function, and evolution of coronavirus spike proteins. Annual review of virology. 2016; 3: 237-61.

Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020; 12: e7355.

Ramphul K, Mejias SG. Coronavirus disease: a review of a new threat to public health. Cureus. 2020; 12: e7276.

Cao B, Wang Y, Wen D, Liu W, Wang J ,Fan G, et al. Atrialof lopinavir–ritonavir in adults hospitalized with severe Covid- 19. N Engl J Med. 2020; 382:1787-99.

Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020; 55: 105932.

Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral research. 2013; 100: 446-54.

Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proceedings of the Japan Academy, Series B. 2017; 93: 449-63.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. New England Journal of Medicine. 2020; 382: 2327-36.

Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics. 2020; 14: 58-60.

Boriskin Y, Leneva I, Pecheur EI, Polyak S. Arbidol: a broad- spectrum antiviral compound that blocks viral fusion. Current medicinal chemistry. 2008; 15: 997-1005.

De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. International journal of antimicrobial agents. 2009; 33: 307-20.

Lim YX, Ng YL, Tam JP, Liu DX. Human coronaviruses: a

review of virus–host interactions. Diseases. 2016; 4: 26.

Singhal T. A review of coronavirus disease-2019 (COVID-19).

The Indian Journal of Pediatrics. 2020; 57: 1-6.

ChenN,ZhouM,DongX,QuJ,GongF,HanY,etal. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020; 395: 507-13.

Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, et al. An update on current therapeutic drugs treating COVID-19.Current Pharmacology Reports. 2020: 1.

Siegel D, Hui HC, Doerffler E, Clarke MO, Chun K, Zhang L, et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo [2, 1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. ACS Publications. J. Med. Chem. 2017; 60: 1648–61.

Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nature Communications. 2020; 11: 222.

WangM,CaoR,ZhangL,YangX,LiuJ,XuM,etal. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research. 2020; 30: 269-71.

Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine. 2020.

Rynes R. Antimalarial drugs in the treatment of rheumatological diseases. Rheumatology. 1997; 36: 799- 805.

Schultz KR, Gilman AL. The lysosomotropic amines, chloroquine and hydroxychloroquine: a potentially novel therapy for graft-versus-host disease. Leukemia & lymphoma. 1997; 24: 201-10.

Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr M, Hijlkema KJ, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018; 14: 1435-55.

Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. The Lancet infectious diseases. 2006; 6: 67-9.

Silva JCd, Mariz HA, Rocha Júnior LFd, Oliveira PSSd, Dantas AT, Duarte ALBP, et al. Hydroxychloroquine decreases Th17- related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients. Clinics. 2013; 68: 766-71.

Cao X. COVID-19: immunopathology and its implications for therapy. Nature reviews immunology. 2020; 20: 269-70.

Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management

of SARS-CoV-2 infection. CMAJ. 2020; 192: E450-E3.

Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, et al. The synthetic antiviral drug arbidol inhibits globally prevalent pathogenic viruses. Journal of virology. 2016; 90: 3086-92.

Villalaín J. Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes. The journal of physical chemistry B. 2010; 114: 8544-54.

Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection. 2020; 18: e1-e5.

Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus arbidol for COVID-19: a randomized

clinical trial. MedRxiv. 2020.

Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. Journal of Korean medical science. J Korean Med Sci. 2020; 35: e79.

De Clercq E. New nucleoside analogues for the treatment of hemorrhagic fever virus infections. Chemistry–An Asian Journal. 2019; 14: 3962-8.